Sign inJoin waitlistJoin the waitlist

Marc Hoffmann

Associate Professor, Marc Hoffmann, Hematologic Malignancies and Cellular Therapeutics · University of Kansas School of Medicine

Credentials: · · · · · · ·

History

University of Kansas School of Medicine
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2011–2014
Hospital of the University of Pennsylvania
2008–2011
Perelman School of Medicine at the University of Pennsylvania
2004–2008

Research

Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access
Transplantation and Cellular Therapy · 2022 · 140 citations
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)
Clinical Cancer Research · 2021 · 92 citations
Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Review · Transplantation and Cellular Therapy · 2023 · First of 5 authors · Corresponding · 73 citations

NA
Nausheen Ahmed
6 papers
Joseph McGuirk
5 papers
Priyanka Sharma
5 papers
Qamar Khan
5 papers
Alvaro Alencar
4 papers
CC
Catherine Coombs
4 papers
DT
Donald Tsai
4 papers
Jennifer Woyach
4 papers
JB
Joseph Bennett
4 papers · 4 as a resident
LW
Luhua Wang
4 papers
Manish Patel
4 papers
Nirav Shah
4 papers

Clinical trials

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2038
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Site PI · Recruiting · Phase 3
Eastern Cooperative Oncology Group
2025–2075
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2026